[
    [
        {
            "time": "",
            "original_text": "医药行业一周观察：大小市值表现分化 关注二线优质公司的机会",
            "features": {
                "keywords": [
                    "医药行业",
                    "大小市值",
                    "表现分化",
                    "二线优质公司"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业一周观察：大小市值表现分化 关注二线优质公司的机会",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报：新医保目录开始启用 关注结构性变化下的投资机会",
            "features": {
                "keywords": [
                    "医药生物",
                    "新医保目录",
                    "启用",
                    "结构性变化",
                    "投资机会"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报：新医保目录开始启用 关注结构性变化下的投资机会",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业报告：创新药企商业化能力的再思考",
            "features": {
                "keywords": [
                    "医药生物",
                    "创新药企",
                    "商业化能力",
                    "再思考"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药生物行业报告：创新药企商业化能力的再思考",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]